



## Impact of MTHFR polymorphisms on methylation of MGMT in glioma patients from Northeast China with different folate levels

N. Liu<sup>1</sup>, J. Jiang<sup>1</sup>, Y.J. Song<sup>2</sup>, S.G. Zhao<sup>3</sup>, Z.G. Tong<sup>4</sup>, H.S. Song<sup>1</sup>, H. Wu<sup>1</sup>, J.Y. Zhu<sup>1</sup>, Y.H. Gu<sup>1</sup>, Y. Sun<sup>1</sup>, W. Hua<sup>1</sup> and J.P. Qi<sup>1</sup>

<sup>1</sup>Department of Pathology, First Affiliated Hospital of Harbin Medical University, Nangang District, Harbin, China

<sup>2</sup>Department of Digestive System, First Affiliated Hospital of Harbin Medical University, Harbin, China

<sup>3</sup>Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University, Harbin, China

<sup>4</sup>Department of Surgical Oncology, Fourth Affiliated Hospital of Harbin Medical University, Nangang District, Harbin, China

Corresponding author: J.P. Qi  
E-mail: jipingqi@yeah.net

Genet. Mol. Res. 12 (4): 5160-5171 (2013)

Received March 26, 2013

Accepted August 19, 2013

Published October 29, 2013

DOI <http://dx.doi.org/10.4238/2013.October.29.10>

**ABSTRACT.** Hypomethylation of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter in glioma cells has been associated with temozolomide resistance. S-adenosylmethionine (SAM), which is produced during folate metabolism, is the main source of methyl groups during DNA methylation. As a key enzyme during folate metabolism, polymorphisms of 5,10-methylenetetrahydrofolate reductase (MTHFR) may regulate folate end-products. We investigated the effect of typical polymorphisms of MTHFR (C677T and A1298C) on MGMT methylation based on different serum folate levels in patients with glioma from Northeast China. A total of 275 patients with glioma and 329 without malignant

tumors were tested. Serum folate concentration was assayed by using the electrochemiluminescence immunoassay. MTHFR polymorphisms were detected by Taqman-Fluorescence quantitative polymerase chain reaction (PCR). Methylation-specific PCR was used to assess MGMT methylation. The constituent ratio of glioma patients below the serum folate biological reference value was significantly higher than that of the control population ( $P < 0.001$ ). In patients with oligodendroglioma and glioblastoma, heterozygotes for the A1298C mutation were found in higher frequency than homozygotes or wild types (oligodendroglioma,  $P < 0.001$ ; glioblastoma,  $P < 0.01$ ). When grouped by the median or biological reference value of serum folate, only homozygotes for C677T with low levels of folate were significantly associated with decreased methylation of MGMT (median,  $P < 0.001$ ; biological reference value,  $P = 0.036$ ). These data suggest that, in combination with a negative folate balance in glioma patients, T/T genotypes in MTHFR C677T may be associated with MGMT demethylation.

**Key words:** Glioma; MGMT; MTHFR; Polymorphisms; Folate